"Lower Cholesterol Means Safer Outcomes"... Reduces Myocardial Infarction and Stroke by 30%
Severance Research Team Tracks 3,000 Atherosclerotic Cardiovascular Disease Patients for Three Years
Greater Effectiveness Achieved with LDL Cholesterol Target Below 55 mg/dL
No Difference in Safety, Including Diabetes Incidence and Liver En
A new study has found that lowering LDL cholesterol levels in patients with atherosclerotic cardiovascular disease more aggressively than previous targets is more effective in preventing the recurrence of myocardial infarction or stroke.
The research team of Professors Byung-Gu Kang, Yong Jun Lee, and Seung Jun Lee from the Division of Cardiology at Severance Hospital, Yonsei University, tracked 3,048 patients with atherosclerotic cardiovascular disease recruited from 17 medical institutions across Korea for three years. On March 30, they reported that the "intensive target group," whose LDL cholesterol levels were reduced to below 55 mg/dL, had an incidence of major cardiovascular events more than 30% lower than the group maintained at below 70 mg/dL according to existing guidelines.
Patients with atherosclerotic cardiovascular disease are considered a high-risk group with a significant risk of recurrence of major cardiovascular events such as myocardial infarction or stroke. For these patients, the primary goal of dyslipidemia treatment is to lower LDL cholesterol. Previous studies have focused on whether intensive statin therapy, ezetimibe, or PCSK9 inhibitors can reduce cholesterol levels and the risk of cardiovascular events.
However, these studies primarily evaluated the efficacy of specific drugs, so there has been a lack of research validating concrete LDL cholesterol targets. While recent dyslipidemia treatment guidelines have lowered the LDL cholesterol target for patients with atherosclerotic cardiovascular disease from below 70 mg/dL to below 55 mg/dL, there was no direct evidence on whether this change in target leads to tangible cardiovascular benefits.
The research team divided patients into two groups: an intensive target group with an LDL cholesterol goal of below 55 mg/dL and a standard target group with a goal of below 70 mg/dL, and compared treatment outcomes. During the follow-up period, statin dosages were adjusted and ezetimibe was added to achieve the target LDL cholesterol level, with PCSK9 inhibitors used as needed.
As a result, the incidence of major events, including cardiovascular death, myocardial infarction, and stroke, was 6.6% in the intensive target group, which was significantly lower than the 9.7% in the standard target group. The rates of nonfatal myocardial infarction and revascularization procedures were also notably lower in the intensive target group.
In the safety analysis, there were no significant differences between the two groups in terms of most adverse events, including new-onset diabetes, worsening glycemic control, muscle-related side effects, or elevations in liver enzymes. Interestingly, the incidence of increased creatinine related to kidney function was actually lower in the intensive target group (1.2%) compared to the standard target group (2.7%).
Professor Byung-Gu Kang stated, "This is the first study to demonstrate that a more aggressive LDL cholesterol target strategy in patients with atherosclerotic cardiovascular disease can actually lead to a reduction in cardiovascular events," adding, "We expect these findings will serve as important evidence supporting the stricter LDL cholesterol targets presented in current dyslipidemia treatment guidelines."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This research was presented on the opening day of the 'Late-Breaking Clinical Trials (LBCT)' session at the 2026 American College of Cardiology (ACC) scientific meeting, and was published in the international journal New England Journal of Medicine (NEJM, IF 78.5).
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.